Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 5.2% - Still a Buy?

Key Points

• The stock price of Sarepta Therapeutics (NASDAQ:SRPT) increased by 5.2%, reaching a last trading price of $18.38, despite a significant drop in trading volume.
• Analyst ratings for Sarepta are mixed, with a consensus rating of "Hold" and various price targets ranging from $12.00 to $80.00, indicating a potential 179% upside according to some analysts.
• Sarepta Therapeutics reported strong earnings, with an EPS of $2.02 for the recent quarter, significantly exceeding analysts' expectations and showing a 68.4% year-over-year revenue growth.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report)'s stock price rose 5.2% during mid-day trading on Tuesday . The company traded as high as $18.84 and last traded at $18.38. Approximately 1,849,531 shares traded hands during mid-day trading, a decline of 71% from the average daily volume of 6,309,413 shares. The stock had previously closed at $17.47.

Analyst Ratings Changes

SRPT has been the topic of a number of recent analyst reports. Needham & Company LLC reissued an "underperform" rating on shares of Sarepta Therapeutics in a research note on Monday, July 28th. Scotiabank raised shares of Sarepta Therapeutics from a "sector perform" rating to a "sector outperform" rating and set a $80.00 price objective on the stock in a research note on Friday, June 6th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Sarepta Therapeutics to $12.00 and gave the company a "sell" rating in a research note on Friday, August 15th. Oppenheimer raised shares of Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $30.00 to $37.00 in a research note on Tuesday, July 29th. Finally, Barclays raised shares of Sarepta Therapeutics from an "underweight" rating to an "equal weight" rating and set a $22.00 target price on the stock in a research note on Tuesday, July 29th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and six have assigned a Sell rating to the company. According to data from MarketBeat, Sarepta Therapeutics currently has a consensus rating of "Hold" and an average target price of $39.32.

Sarepta Therapeutics Trading Up 5.9%

The company has a market cap of $1.81 billion, a P/E ratio of -21.26 and a beta of 0.49. The company has a quick ratio of 1.81, a current ratio of 2.89 and a debt-to-equity ratio of 0.84. The firm's 50 day moving average is $17.75 and its two-hundred day moving average is $39.77.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.89 by $1.13. The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. Sarepta Therapeutics's revenue for the quarter was up 68.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.07 earnings per share. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in Sarepta Therapeutics by 27.9% during the 1st quarter. Wellington Management Group LLP now owns 2,646,619 shares of the biotechnology company's stock worth $168,907,000 after buying an additional 577,848 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in Sarepta Therapeutics by 2.1% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,997,991 shares of the biotechnology company's stock worth $127,512,000 after buying an additional 41,408 shares during the period. Geode Capital Management LLC raised its stake in Sarepta Therapeutics by 3.0% during the 2nd quarter. Geode Capital Management LLC now owns 1,875,997 shares of the biotechnology company's stock worth $32,085,000 after buying an additional 55,076 shares during the period. Federated Hermes Inc. raised its stake in Sarepta Therapeutics by 347.8% during the 2nd quarter. Federated Hermes Inc. now owns 1,308,199 shares of the biotechnology company's stock worth $22,370,000 after buying an additional 1,016,069 shares during the period. Finally, EcoR1 Capital LLC raised its holdings in shares of Sarepta Therapeutics by 67.8% in the 1st quarter. EcoR1 Capital LLC now owns 1,292,386 shares of the biotechnology company's stock worth $82,480,000 after acquiring an additional 522,386 shares during the last quarter. Institutional investors own 86.68% of the company's stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.